Indoor Tanning and Melanoma Risk: Molecular and Epidemiological Evidence
December 29, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Altraday, Raceclo, Ace-Proxyvon, Zix-R, Justaday, Nuflam-RB, Ntire, Freenac
Synonyms :
aceclofenac/rabeprazole
Class :
NSAIDs
Brand Name :
Altraday, Raceclo, Ace-Proxyvon, Zix-R, Justaday, Nuflam-RB, Ntire, Freenac
Synonyms :
aceclofenac/rabeprazole
Class :
NSAIDs
Dosage Forms & Strengths
Tablet
200mg/20mg
Capsule
200mg/20mg
(aceclofenac/rabeprazole)
Take one tablet orally daily
Dosage Forms & Strengths
Tablet
200mg/20mg
(aceclofenac/rabeprazole)
Capsule
200mg/20mg
(aceclofenac/rabeprazole)
for 13 to 18 years old:
Take one tablet orally daily
Refer to adult dosing
may enhance the serum concentration when combined with lithium
may enhance the serum concentration when combined with lithium
may decrease the diuretic effect when combined with loop diuretics
may decrease the diuretic effect when combined with loop diuretics
may decrease the diuretic effect when combined with loop diuretics
choline magnesium trisalicylate
may have an increasingly adverse effect when combined with salicylates
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may enhance the serum concentration when combined with lithium
may enhance the serum concentration when combined with lithium
may have an increased antiplatelet effect when combined with nonsteroidal anti-inflammatory agents
may have an increased antiplatelet effect when combined with nonsteroidal anti-inflammatory agents
may have an increased antiplatelet effect when combined with nonsteroidal anti-inflammatory agents
may have an increased antiplatelet effect when combined with nonsteroidal anti-inflammatory agents
may have an increased antiplatelet effect when combined with nonsteroidal anti-inflammatory agents
may diminish the rate of excretion which results in a higher serum level
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may enhance the concentration of serum when combined with lithium
may enhance the concentration of serum when combined with lithium
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
edoxaban: it may enhance the toxic effect of Nonsteroidal Anti-Inflammatory Agents
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may diminish the rate of excretion leading to a higher serum level
may decrease the diuretic effect of loop diuretics
may decrease the diuretic effect of loop diuretics
may decrease the diuretic effect of loop diuretics
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may diminish the effects of indomethacin by pharmacodynamic antagonism
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
spironolactone and hydrochlorothiazide
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may diminish the therapeutic efficacy of each other when used in combination
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may diminish the excretion when combined with aminoglycosides
neomycin/polymyxin B/bacitracin topical
may diminish the excretion when combined with aminoglycosides
may diminish the excretion when combined with aminoglycosides
may diminish the excretion when combined with aminoglycosides
may diminish the excretion when combined with aminoglycosides
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may have an increased hyperkalemic effect when combined with potassium salts
may decrease the therapeutic effect when combined with beta-blockers
may have an increased nephrotoxic effect when combined with 5-aminosalicylic acid
may have an increased nephrotoxic effect when combined with 5-aminosalicylic acid
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increased adverse effect when combined with corticosteroids
may have an increased adverse effect when combined with corticosteroids
may have an increased adverse effect when combined with corticosteroids
may have an increased adverse effect when combined with corticosteroids
may have an increased adverse effect when combined with corticosteroids
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may diminish the excretion when combined with aminoglycosides
neomycin/polymyxin B/bacitracin topical
may diminish the excretion when combined with aminoglycosides
may diminish the excretion when combined with aminoglycosides
may diminish the excretion when combined with aminoglycosides
may diminish the excretion when combined with aminoglycosides
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may decrease the antihypertensive effect when combined with beta-blockers
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may decrease the therapeutic effect when combined with prostaglandins (ophthalmic)
may decrease the therapeutic effect when combined with prostaglandins (ophthalmic)
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with 5-aminosalicylic acid
may have an increased nephrotoxic effect when combined with 5-aminosalicylic acid
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with bisphosphonate derivatives
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may diminish the absorption when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
enoxaparin: it may enhance the toxic effect of Nonsteroidal Anti-Inflammatory Agents
may enhance the renal tubular clearance for anionic drug competition
may have an increased nephrotoxic effect when combined with 5-aminosalicylic acid
may have an increased nephrotoxic effect when combined with 5-aminosalicylic acid
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
NSAID
Actions and Spectrum
aceclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that primarily functions as an analgesic and anti-inflammatory agent. It works by inhibiting the enzymes COX-1 and COX-2, which are involved in the production of prostaglandins.
rabeprazole is a proton pump inhibitor (PPI) that works by reducing the production of stomach acid. It inhibits the proton pump in the stomach lining which is responsible for acid secretion.
Frequency not defined
Diarrhea
Nausea
Dyspepsia
Abdominal pain
Dizziness
Rashes
Nephrotoxicity
Blood dyscrasias
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Caution:
Pregnancy consideration:
Pregnancy category: N/A
Lactation: Excretion into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
aceclofenac primarily inhibits the enzymes COX-1 and COX-2, which are responsible for the production of prostaglandins, these are chemicals that mediate pain, inflammation, and fever.
rabeprazole is a proton pump inhibitor (PPI). By inhibiting the proton pump, rabeprazole reduces the production of gastric acid, leading to decreased acidity in the stomach.
Pharmacodynamics
aceclofenac’s anti-inflammatory and analgesic effects are both peripheral and central. It can help relieve pain and inflammation locally and reduce the perception of pain in the brain.
rabeprazole’s acid-suppressing action allows the stomach and duodenal ulcers to heal by reducing acid-related damage to the mucosal lining.
Pharmacokinetics
Absorption
aceclofenac/rabeprazole both well-absorbed after oral administration.
Distribution
aceclofenac is extensively distributed throughout the body.
While rabeprazole has a relatively short half-life and is not highly distributed into tissues.
Metabolism
aceclofenac/rabeprazole both undergoes hepatic metabolism.
Elimination and excretion
aceclofenac/rabeprazole both are excreted through the urine.
Administration
aceclofenac/rabeprazole is taken orally and it is in tablets and capsules form.
Patient information leaflet
Generic Name: aceclofenac/rabeprazole
Why do we use aceclofenac/rabeprazole?
aceclofenac/rabeprazole is a combination drug used in treatment of Rheumatoid arthritis.
aceclofenac/rabeprazole is also used in treatment of Osteoarthritis and Ankylosing spondylitis.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
